Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Proveca
Proveca
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Sialanar
Glycopyrronium
2016-09-15
—
Aqumeldi
Enalapril
2023-11-15
2032-2036
Heart failure
,
Diabetic nephropathies
,
Left ventricular dysfunction
,
Rheumatoid arthritis
,
Edema
,
Malignant hypertension
,
Bartter syndrome
,
Hypertension
,
Nephrotic syndrome
,
Variant angina pectoris
,
Atrial fibrillation
,
Myocardial infarction
,
Atrial flutter
,
Supraventricular tachycardia
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Glycopyrronium
respiratory aspiration
,
covid-19
,
disease progression
,
chronic obstructive pulmonary disease
,
obstructive lung diseases
,
asthma
,
lung diseases
Isoxaflutole
healthy volunteers/patients
,
cardiovascular diseases
,
asthma
,
alzheimer disease
,
leukemia
,
myeloid leukemia acute
,
myeloid leukemia
,
pain
,
rheumatoid arthritis
,
arthritis
,
neoplasms
,
neoplasm metastasis
,
triple negative breast neoplasms
,
parkinson disease
,
psychotic disorders
,
mental disorders
,
heart failure
,
breast neoplasms
,
non-small-cell lung carcinoma
,
prostatic neoplasms
,
pancreatic neoplasms
,
sarcoma
,
ovarian neoplasms
,
endometrioid carcinoma
,
mucinous cystadenocarcinoma
,
fallopian tube neoplasms
,
acinar cell carcinoma
,
type 2 diabetes mellitus
,
diabetes mellitus
,
chronic obstructive pulmonary disease
,
lung diseases
,
obstructive lung diseases
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use